StockData

Merck vs Dr Reddys Laboratories

MRK and RDY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MRK and RDY compare

Merck grew revenue faster over the last twelve months (4.9% versus 3.2% for Dr Reddys Laboratories).

Dr Reddys Laboratories keeps more of each dollar of sales as profit, with a net margin of 12.8% compared with 3.6% at Merck.

Merck pays a dividend yielding 2.3%; Dr Reddys Laboratories does not pay one.

Merck scores higher on the StockData Score (10 against 7 for Dr Reddys Laboratories), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMRKRDY
Size and price
Market cap$363B–
Share price$146.95$14.74
Change, 1 year61.6%6.4%
Change, 5 years82.1%18.2%
Beta (5Y)0.220.35
Employees75K–
StockData Score
Total score10 (better)7
Valuation score00
Growth score01 (better)
Performance score3 (better)2
Health score44
Dividend score3 (better)0
Valuation
P/E151×–
P/S5.4×–
P/B8.1×–
P/FCF24.6×–
PEG17.96–
FCF yield4.1%–
Fair value$71.32–
Margin of safety−106%–
Growth
Revenue growth (TTM)4.9% (better)3.2%
Revenue growth, 5Y average9.4%12.1% (better)
Net income growth (TTM)−87.1%−24.2% (better)
EPS growth (TTM)−87.2%−24.1% (better)
EPS growth, 5Y average21.2% (better)19.9%
Profitability
Gross margin71.8% (better)52.8%
Operating margin–15.0%
Net margin3.6%12.8% (better)
FCF margin21.9% (better)10.0%
Return on equity5.1%12.1% (better)
Return on invested capital–9.7%
Financial health
Debt / equity1.200.21 (better)
Net debt / EBITDA–0.87
Interest coverage–13.5×
Current ratio1.351.80 (better)
Altman Z-score3.77–
Piotroski F-score44
Dividends and buybacks
Dividend yield2.3%–
Payout ratio341%15.5%
Years of dividend growth15 (better)0
Dividend growth, 5Y average5.8%9.9% (better)
Buyback yield0.98%–
Shareholder yield3.3%–
Ownership
Held by institutions80.3%15.1%
Held by insiders0.05%13.6%
Insider net buying, 12 months−$70.7M–
Superinvestors holding4–
Short interest, % of float1.1%–

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.